Early access
Sign in
Enrolling by invitationNo phase

Tracks new adult medullary thyroid cancer cases over time

Records new adult thyroid cancer cases to watch for changes linked to diabetes drugs.

Key facts

Who runs it
Novo Nordisk A/S
Where
Morgantown, United StatesSee the site
Trial code
Registry title
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Status
Enrolling by invitation
People taking part
6,750 people, planned
Started
Jan 2012
Expected to end
Dec 2039
Type of study
Observational
Treatments tested
  • No treatment given
Record updated
13 June 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The study looks for adults whose medullary thyroid carcinoma (MTC) is recorded in a state or regional population-based cancer registry. It tracks new MTC cases each year. No treatment is given.

Age
18 years or older
Sex
All sexes can join.
Disease stage
A record of medullary thyroid carcinoma (MTC) in a state or regional population-based cancer registry.

Main reasons for not taking part

  • The record says there are no other inclusion or exclusion criteria.

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • A record of medullary thyroid carcinoma (MTC) identified from state/regional population-based cancer registries
  • At least 18 years or older; There are no other inclusion or exclusion criteria

Where in United States

  • United BioSource LLCMorgantown, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.

The group in the trial

  • Questionnaire

    None. Non-interventional study.

    Treatment: No treatment given

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry
Plain-language title
Tracks new adult medullary thyroid cancer cases over timeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 June 2023